Carerx Corporation · TSX:CRRX
Carerx — Q4 2020 Earnings Presentation
15 slides from Carerx's earnings presentation, Mar 11, 2021
Slide 1: Q4 2020 Earnings Call
Slide 2: Forward Looking Statements
Forward Looking Statements Certain of the statements contained in this presentation are "forward looking information within the meaning of applicable Canadian securities legislation. Forward looking information includes, but is not limited to, business strategy, plans and other expectations, beliefs
Slide 3: David Murphy, President & Chief Executive Officer
David Murphy President & Chief Executive Officer
Slide 4: A Very Strong Finish to a Transformational Year
Q4 2020 A Very Strong Finish to a Transformational Year Continued Financial Momentum Completion of Remedy’s Integration Ahead of Schedule
Slide 5: Q4 & Full Year 2020 Financial Highlights
Q4 & Full Year 2020 Financial Highlights From Continuing Operations (+/- compared to Q4 2019 & Full Year 2019) . Q4/20 average Beds 7 a4 Full Year Serviced of 48,768 (millions except bed count) +55% vs Qa/i9 Revenue $46.4 +44% $162.2 +30% * Q4/20 Adjusted Adjusted EBITDA $41 +65% $12.8 +36% EBITDA m
Slide 6: Bed count and growth charts
50,000 40,000 30,000 20,000 2014 2015 2016 2017 2018 2019 2020 2018 2019 2020 2018 2019 2020
Slide 7: SmartMeds: Another High-Quality Tuck-In Acquisition
SmartMeds: Another * Closing consideration of $4 M cash High-Quality Tuck-In plus $475,000 common shares! Acquisition * Earn-out component of up to an * Acquisition of SmartMeds Pharmacy: additional ~$2.9 M? * Will add 2,400 beds * ROFR to acquire proprietary * Strengthens market position in Ontario
Slide 8: Other Highlights
Other Highlights Q4/20 ¢ Signed a multi-year contract with an Ontario-based seniors home operator + Added ~1,100 new retirement and long-term care residents across 13 seniors housing communities Subsequent to Quarter End * Completed an equity financing for total gross proceeds of $21.2 M
Slide 9: Andrew Mok, Chief Financial Officer
Andrew Mok Chief Financial Officer
Slide 10: Q4 2019 vs Q4 2020 results charts
50 • 45 40 • 35 30 25 • 20 15 10 5 0 Q4 2019 Q4 2020
Slide 11: Q4 2020 Financial Results | Adjusted EBITDA
Q4 2020 Financial Results | Adjusted EBITDA Nh Bb $2.5 Q4 2019 (millions) $4.1 Q4 2020 65% year-over-year growth Remedy’s contributed $1.6 M Realized $0.5 M in cost synergies from Remedy’s integration ODBA amendments reduced Adjusted EBITDA by $0.3 million, which was fully offset by other operating
Slide 12: Balance Sheet and Cash Flows
Balance Sheet and Cash Flows (millions except ratio) At Dec. 31/20 Cash $19.6 Net Debt! $38.5 Net Debt to Adjusted EBITDA? 2.4x Q4 2020 Cash provided by operations $2.8 Includes $1.5 M generated from divestiture of a non-operating, shell subsidiary Post Q4 - Completed a $21.2 M combined public offer
Slide 13: David Murphy, President & Chief Executive Officer
David Murphy President & Chief Executive Officer
Slide 14: Strengthened Position for Continued Growth
Strengthened Position for Continued Growth Continue to consolidate a highly fragmented industry Make strategic, accretive acquisitions to 2023 Ta rget increase scale and realize operational efficiencies ] 6) 0, 6) O 0) Conti t d bed ontinue to expand beds beds under contract Well capitalized and pos
Slide 15: Questions
/ *.. Questions \ Wee Visit our website at www.carerx.ca | Follow @CareRx on Twitter $3 CareRx